Plant-based Expression Systems market size is projected to grow at a compound annual growth rate (CAGR) of 5.4% from 2022 to 2030. In recent years, the plant-based expression system has gained significant attention for its characteristics of high compatibility with culture media, safety, and low cost. Plant expression systems are a practical option for producing antibodies, vaccines, and complex biomolecules because of their advantages: lower prices, high flexibility to scale up, environment friendly, and low contamination risks.
Several factors such as the increasing chronic diseases, high requirement of the research process for protein expression, surging R&D initiatives for disease therapeutics, growing government funding for commercialization of plant expression technologies, and advancements in plant expression systems are expected to favour the development of the plant-based expression systems market during the forecast period. A wide range of pharmaceutical antibodies has been expressed in plants. Hence, plant-based protein expression systems are becoming more critical to scale production and meet market demands. However, the high costs of instruments and protein expression reagents may hinder the growth of the market.
The plant-based expression systems market is segmented into the product, plant, type of service, expression system, and region. By product, the market comprises biosimilars, cell therapies, gene therapies, monoclonal antibodies, vaccines, and others. The vaccines and monoclonal antibodies accounted for the largest market share in 2021, owing to the rising prevalence of cancer and cardiovascular diseases. The market is classified into algae, barley, benth, duckweed, lettuce, maize, moss, rice, tomato, tobacco, and wheat germ in terms of the plant. The type of service segment is grouped into research and development, manufacturing, fill/finish, and others. By expression system, the market is divided into stable expression system and transient expression system. The transient expression system is expected to dominate the market in the upcoming years due to its benefits, such as producing high yield, environment friendly, scalability, uniformity and consistency of product accumulation. The market is being studied throughout North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America is projected to lead the plant-based expression systems market over the forecast years, followed by Asia-Pacific. The factors such as the fast adoption of advanced technologies, high demand for protein therapeutics, and the rising R&D investments in plant expression technologies.
Some of the key players operating in the plant-based expression systems market are Medicago, Leaf Expression Systems, Eleva, iBIO, Creative Biogene, PlantForm, Protalix BioTherapeutics, Inc., G+Flas Life Sciences, Kentucky Bioprocessing, Angany, and others.
- Leaf Expression Systems
- Creative Biogene
- Protalix BioTherapeutics, Inc.
- G+Flas Life Sciences
- Kentucky Bioprocessing
- Other Prominent Players